Women's Health

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...

Secretary Robert F. Kennedy Jr. announced that the CDC will no longer recommend the COVID-19 booster vaccine for healthy children and pregnant people. The announcement comes despite previous CDC...

The nasal spray is the first vaccine for the prevention of influenza that does not need to be administered by a health care provider.

In June, following a placebo-controlled trial, the FDA approved pembrolizumab with chemotherapy to treat patients with primary advanced or recurrent endometrial carcinoma.

The first orally disintegrating birth control tablet was designed for individuals who have trouble swallowing their medication.

Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

The FDA has approved the first daily oral contraceptive for the prevention of pregnancy that does not require a health care provider’s prescription.

The US FDA recently approved a novel treatment for moderate to severe vasomotor symptoms that are caused by menopause.